CN104203247B - 用于治疗眼部病症的4‑孕甾烯‑11ss‑17‑21‑三醇‑3，20‑二酮衍生物 - Google Patents

用于治疗眼部病症的4‑孕甾烯‑11ss‑17‑21‑三醇‑3，20‑二酮衍生物 Download PDF

Info

Publication number
CN104203247B
CN104203247B CN201280065948.4A CN201280065948A CN104203247B CN 104203247 B CN104203247 B CN 104203247B CN 201280065948 A CN201280065948 A CN 201280065948A CN 104203247 B CN104203247 B CN 104203247B
Authority
CN
China
Prior art keywords
group
compound
condition
ocular
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280065948.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN104203247A (zh
Inventor
J·L·埃德尔曼
A·奈莫
T·C·马龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47179019&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104203247(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CN104203247A publication Critical patent/CN104203247A/zh
Application granted granted Critical
Publication of CN104203247B publication Critical patent/CN104203247B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0053—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280065948.4A 2011-11-11 2012-11-09 用于治疗眼部病症的4‑孕甾烯‑11ss‑17‑21‑三醇‑3，20‑二酮衍生物 Expired - Fee Related CN104203247B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161558775P 2011-11-11 2011-11-11
US61/558,775 2011-11-11
PCT/US2012/064293 WO2013071009A1 (en) 2011-11-11 2012-11-09 4 - pregenen- 11ss - 17 - 21 -triol-3, 20 -dione derivatives for the treatment of ocular conditions

Publications (2)

Publication Number Publication Date
CN104203247A CN104203247A (zh) 2014-12-10
CN104203247B true CN104203247B (zh) 2017-06-06

Family

ID=47179019

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201280066021.2A Expired - Fee Related CN104185472B (zh) 2011-11-11 2012-11-09 4‑孕甾烯‑11β‑17‑21‑三醇‑3，20‑二酮衍生物的药物组合物和使用方法
CN201280065948.4A Expired - Fee Related CN104203247B (zh) 2011-11-11 2012-11-09 用于治疗眼部病症的4‑孕甾烯‑11ss‑17‑21‑三醇‑3，20‑二酮衍生物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201280066021.2A Expired - Fee Related CN104185472B (zh) 2011-11-11 2012-11-09 4‑孕甾烯‑11β‑17‑21‑三醇‑3，20‑二酮衍生物的药物组合物和使用方法

Country Status (24)

Country Link
US (7) US8865691B2 (enExample)
EP (2) EP2776041A1 (enExample)
JP (2) JP6216719B2 (enExample)
KR (2) KR20140095549A (enExample)
CN (2) CN104185472B (enExample)
AR (1) AR088846A1 (enExample)
AU (3) AU2012335590B2 (enExample)
BR (2) BR112014011333B1 (enExample)
CA (3) CA2855290C (enExample)
CL (2) CL2014001243A1 (enExample)
CO (2) CO6970598A2 (enExample)
ES (1) ES2806603T3 (enExample)
HK (1) HK1200366A1 (enExample)
IL (2) IL232534A0 (enExample)
IN (2) IN2014CN03903A (enExample)
MX (3) MX365859B (enExample)
MY (2) MY172227A (enExample)
PH (2) PH12014501079B1 (enExample)
RU (2) RU2688159C2 (enExample)
SG (3) SG10201603766PA (enExample)
TW (1) TWI584809B (enExample)
UA (2) UA111867C2 (enExample)
WO (2) WO2013071009A1 (enExample)
ZA (2) ZA201403431B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2386555A1 (en) 2010-05-13 2011-11-16 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities
EP2592078A1 (en) 2011-11-11 2013-05-15 Almirall, S.A. New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ
HK1215166A1 (zh) 2012-12-18 2016-08-19 Almirall, S.A. 具有β2肾上腺素激动剂及M3毒蕈碱拮抗剂活性的新型环己基和奎宁环基氨基甲酸酯衍生物
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
AR098747A1 (es) * 2013-12-13 2016-06-08 Allergan Inc Formas polimórficas de un compuesto similar a esteroides y métodos para su preparación y uso
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
RU2746083C2 (ru) 2015-03-05 2021-04-06 Аллерган, Инк. Самоэмульгирующиеся системы доставки лекарств (sedds) для доставки офтальмологического лекарства
US20190216726A1 (en) * 2016-09-16 2019-07-18 Kala Pharmaceuticals, Inc. Particles, Compositions and Methods for Ophthalmic and/or Other Applications
WO2019055028A1 (en) * 2017-09-15 2019-03-21 Kala Pharmaceuticals, Inc. PARTICLES, COMPOSITIONS AND METHODS FOR OPHTHALMIC APPLICATIONS AND / OR OTHER APPLICATIONS
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
US4242334A (en) * 1977-08-04 1980-12-30 Hoechst Aktiengesellschaft Corticoid 17-(alkyl carbonates) and processes for their preparation
US5362721A (en) * 1990-08-10 1994-11-08 Hoechst Aktiengesellschaft Corticoid-17-alkyl-carbonates substituted in the 17-position, process for their preparation and pharmaceuticals containing them
WO2005099715A3 (en) * 2004-04-08 2006-08-03 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6605514A (enExample) * 1966-04-25 1967-10-26
IT1056711B (it) * 1967-04-01 1982-02-20 Vismara F Spa Derivati dell idrocortisone
US3484436A (en) * 1967-09-07 1969-12-16 Syntex Corp Bicyclo(2.2.2)octane - 1 - -carboxylate esters of delta**4 - pregnene corticoid steroids
GB1227992A (enExample) 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
US3693032A (en) 1971-04-23 1972-09-19 Ibm Antisaturation technique for ttl circuits
JPS52136157A (en) * 1976-04-14 1977-11-14 Taisho Pharmaceut Co Ltd Preparation of steroid 17-esters
JPS60994B2 (ja) * 1976-07-26 1985-01-11 大正製薬株式会社 プレグナン系化合物の１７α―エステル類の製造法
US4221787A (en) * 1978-03-28 1980-09-09 Interx Research Corporation Esteramide prodrugs of anti-inflammatory corticosteroids
US4221778A (en) * 1979-01-08 1980-09-09 Pennwalt Corporation Prolonged release pharmaceutical preparations
US6011023A (en) * 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
MXPA02003731A (es) * 1999-10-15 2003-12-11 Leo Pharm Prod Ltd Derivados novedosos de acido fusidico.
US6395721B1 (en) 2000-01-05 2002-05-28 Leonard Bloom Low potency unpreserved sterile topical corticosteroid compositions for dermatitis
NZ538932A (en) * 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
JP2005008596A (ja) * 2003-06-20 2005-01-13 Kobayashi Pharmaceut Co Ltd 眼科用組成物
BRPI0513243B8 (pt) 2004-07-12 2021-05-25 Allergan Inc composições oftálmicas e respectivos usos
US7687484B2 (en) * 2006-05-25 2010-03-30 Bodor Nicholas S Transporter enhanced corticosteroid activity
US7691811B2 (en) * 2006-05-25 2010-04-06 Bodor Nicholas S Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye
PT1864667E (pt) * 2006-06-01 2013-11-18 Novagali Pharma Sa Uso de pró-fármacos para administração intravítrea ocular
ES2493641T3 (es) * 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
JP2009053880A (ja) 2007-08-27 2009-03-12 Sony Broadband Solution Corp 情報処理装置、ならびにｃｐｕユニット
WO2009085879A2 (en) * 2007-12-21 2009-07-09 Schering Corporation C20-c21 substituted glucocorticoid receptor agonists
KR102080429B1 (ko) * 2008-06-26 2020-02-21 안테리오스, 인코퍼레이티드 경피 운반
UA111867C2 (uk) 2011-11-11 2016-06-24 Аллерган, Інк. ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3984544A (en) * 1975-02-28 1976-10-05 Schering Corporation Retinoic acid esters of steroids of the pregnane series, their use in the treatment of acne and pharmaceutical formulations useful therefor
US4242334A (en) * 1977-08-04 1980-12-30 Hoechst Aktiengesellschaft Corticoid 17-(alkyl carbonates) and processes for their preparation
US5362721A (en) * 1990-08-10 1994-11-08 Hoechst Aktiengesellschaft Corticoid-17-alkyl-carbonates substituted in the 17-position, process for their preparation and pharmaceuticals containing them
WO2005099715A3 (en) * 2004-04-08 2006-08-03 Retmed Pty Ltd Treatment of ophthalmic conditions with mineralcorticoids

Also Published As

Publication number Publication date
CN104185472B (zh) 2017-06-13
NZ624920A (en) 2017-06-30
RU2014123471A (ru) 2015-12-20
SG10201603766PA (en) 2016-07-28
MX2014005678A (es) 2014-12-10
AU2012335590A1 (en) 2014-05-29
US8865691B2 (en) 2014-10-21
IL232534A0 (en) 2014-06-30
US10188667B2 (en) 2019-01-29
WO2013071010A1 (en) 2013-05-16
CO6970609A2 (es) 2014-06-13
MX363669B (es) 2019-03-29
JP2014533274A (ja) 2014-12-11
RU2014123472A (ru) 2015-12-20
MX2014005679A (es) 2014-12-10
ZA201403431B (en) 2016-05-25
NZ624919A (en) 2016-10-28
RU2688159C2 (ru) 2019-05-20
MX365859B (es) 2019-06-18
EP2776040A1 (en) 2014-09-17
KR20140095549A (ko) 2014-08-01
SG11201402247PA (en) 2014-06-27
MX2019006877A (es) 2019-08-22
BR112014011333A2 (pt) 2017-05-02
US8906892B2 (en) 2014-12-09
AU2012335590B2 (en) 2017-10-19
CL2014001243A1 (es) 2014-11-28
ES2806603T3 (es) 2021-02-18
CA2855290C (en) 2017-02-28
WO2013071009A1 (en) 2013-05-16
JP6158201B2 (ja) 2017-07-05
TWI584809B (zh) 2017-06-01
BR112014011333B1 (pt) 2020-04-28
CN104203247A (zh) 2014-12-10
UA111867C2 (uk) 2016-06-24
US9717743B2 (en) 2017-08-01
PH12014501078B1 (en) 2014-07-28
US20130123223A1 (en) 2013-05-16
HK1200367A1 (en) 2015-08-07
CA2855929A1 (en) 2013-05-16
MY172227A (en) 2019-11-18
KR20140095548A (ko) 2014-08-01
US20130123226A1 (en) 2013-05-16
CA2855290A1 (en) 2013-05-16
US20180147217A1 (en) 2018-05-31
AU2018200436A1 (en) 2018-02-08
AU2018200436B2 (en) 2019-10-24
IL232535A0 (en) 2014-06-30
AU2012335589B2 (en) 2017-08-31
MY182222A (en) 2021-01-18
ZA201403430B (en) 2016-05-25
JP6216719B2 (ja) 2017-10-18
IL232535B (en) 2019-09-26
TW201325596A (zh) 2013-07-01
PH12014501078A1 (en) 2014-07-28
US20170182062A1 (en) 2017-06-29
US10493082B2 (en) 2019-12-03
JP2014533275A (ja) 2014-12-11
US9433631B2 (en) 2016-09-06
CA2991883A1 (en) 2013-05-16
CL2014001244A1 (es) 2014-11-14
AU2012335589A1 (en) 2014-05-29
UA116622C2 (uk) 2018-04-25
SG11201402225RA (en) 2014-06-27
AR088846A1 (es) 2014-07-10
CN104185472A (zh) 2014-12-03
CA2991883C (en) 2020-03-10
PH12014501079A1 (en) 2014-07-28
US20190365786A1 (en) 2019-12-05
HK1200366A1 (en) 2015-08-07
RU2683775C2 (ru) 2019-04-02
EP2776041A1 (en) 2014-09-17
PH12014501079B1 (en) 2014-07-28
US20150005519A1 (en) 2015-01-01
IN2014CN03903A (enExample) 2015-10-16
IN2014CN03919A (enExample) 2015-09-04
BR112014011341A2 (pt) 2017-05-02
US20150057258A1 (en) 2015-02-26
EP2776040B1 (en) 2020-04-22
CA2855929C (en) 2018-03-27
KR102049615B1 (ko) 2019-11-28
CO6970598A2 (es) 2014-06-13

Similar Documents

Publication Publication Date Title
CN104203247B (zh) 用于治疗眼部病症的4‑孕甾烯‑11ss‑17‑21‑三醇‑3，20‑二酮衍生物
EP3983384B1 (en) N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
JP7019000B2 (ja) ２環性複素環化合物
UA79229C2 (en) 3-nitrogen-6,7-dioxygen steroids and uses related thereto
TR201808616T4 (tr) Nöroaktif 19-alkoksi-17-ikameli steroidler, bunların ön ilaçları ve bunları kullanan tedavi yöntemleri.
CN117088875A (zh) 一种高活性Wnt通路抑制剂化合物
KR20080039442A (ko) 스테로이드 니트록시 유도체들
CN105263487B (zh) 用于眼科应用的醌基一氧化氮供体化合物
WO2020135454A1 (zh) 一类类固醇化合物及其用途
NZ624919B2 (en) 4-pregenen-11ss-17-21-triol-3,20-dione derivatives for the treatment of ocular conditions
HK1200367B (en) 4-pregenen-11ss-17-21-triol-3, 20-dione derivatives for the treatment of ocular conditions
WO2025256615A1 (zh) 新型糖皮质激素的晶型

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170606

Termination date: 20201109

CF01 Termination of patent right due to non-payment of annual fee